Ken Griffin Akebia Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$0.94 - $1.55 $5,922 - $9,765	-6,300 Reduced 8.13%	71,200 $93,000
Q2 2024 Aug 14, 2024	SELL	$0.86 - $1.63 $110,596 - $209,618	-128,600 Reduced 62.4%	77,500 $79,000
Q1 2024 May 15, 2024	BUY	$1.27 - $2.24 $127,000 - $224,000	100,000 Added 94.25%	206,100 $377,000
Q4 2023 Feb 14, 2024	BUY	$0.8 - $1.28 $42,320 - $67,712	52,900 Added 99.44%	106,100 $131,000
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.84 $13,311 - $28,152	15,300 Added 40.37%	53,200 $60,000
Q2 2023 Aug 14, 2023	BUY	$0.51 - $1.43 $102 - $286	200 Added 0.53%	37,900 $34,000
Q1 2023 May 15, 2023	BUY	$0.56 - $1.15 $10,472 - $21,505	18,700 Added 98.42%	37,700 $21,000
Q4 2022 Feb 14, 2023	SELL	$0.25 - $0.58 $3,375 - $7,829	-13,500 Reduced 41.54%	19,000 $11,000
Q3 2022 Nov 14, 2022	BUY	$0.3 - $0.46 $1,920 - $2,944	6,400 Added 24.52%	32,500 $10,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $379M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.